The clinical efficacy of tocilizumab in rheumatoid arthritis

Publisher Website
Google Scholar
Abstract
Interleukin-6 (IL-6) has emerged as a potential therapeutic target in rheumatoid arthritis (RA). This is based on the greater understanding of the role this cytokine can play in various aspects of the immunopathphysiology of RA. Recently, theory has been put into practice with the assessment of IL-6 inhibitors in clinical trials. The largest amount of data to date comes from trials of the humanized anti-IL-6 receptor antibody tocilizumab. Studies worldwide have demonstrated the clinical efficacy of this agent in patients with RA.

This publication has 0 references indexed in Scilit: